Tadalafil (Generic) FDA Approval History

The Original Brand Approval: How Tadalafil Reached the U.S. Market

The FDA granted NDA 021368 for Cialis (tadalafil) on November 21, 2003, making it the second phosphodiesterase type 5 (PDE5) inhibitor approved for erectile dysfunction in the United States, following sildenafil (Viagra, 1998) and predating vardenafil's approval by about one month. The approval was based on a broad clinical package that included dose-ranging, placebo-controlled, and open-label extension trials across thousands of men. Brock et al. (J Urol 2002) reported statistically significant improvements in erectile function domain scores for tadalafil 10 mg and 20 mg versus placebo in one of the key trials supporting that package, with a combined responder rate that exceeded placebo by more than 30 percentage points 1.

NDA 021368: Scope and Initial Label

The original label covered on-demand dosing at 10 mg and 20 mg. The 2.5 mg and 5 mg daily-dosing regimen, now widely used in men who prefer not to time intercourse, was added through a supplemental NDA after additional efficacy and safety data confirmed adequate 24-hour PDE5 inhibition at those lower doses. The FDA's Office of Drug Evaluation III reviewed the NDA; the complete response and approval letter are publicly accessible in the Drugs@FDA database at accessdata.fda.gov 2.

BPH and PAH Label Expansions

Eli Lilly obtained a supplemental approval for BPH in 2011, allowing tadalafil 5 mg once daily for men with lower urinary tract symptoms attributed to BPH, with or without co-existing erectile dysfunction. That label expansion was grounded in the LVHJ-301 program, a multi-trial series showing statistically significant reductions in International Prostate Symptom Score (IPSS) at 12 weeks versus placebo 3.

Separately, tadalafil 20 mg twice daily under the brand name Adcirca received approval for pulmonary arterial hypertension (WHO Group 1 PAH) under NDA 022332. The PHIRST trial (N=405) demonstrated that tadalafil 40 mg once daily improved 6-minute walk distance by a mean of 33 meters versus placebo at 16 weeks (P<0.001) 4. Generic versions of the PAH formulation entered the market alongside the ED generics in 2018.

Generic Tadalafil: The ANDA Pathway and 2018 Market Entry

Generic drug manufacturers seeking to market tadalafil tablets must file an Abbreviated New Drug Application (ANDA) under 21 U.S.C. 505(j). The core requirement is bioequivalence, meaning the generic must deliver the same active ingredient at the same rate and extent as the reference listed drug (RLD), Cialis.

Bioequivalence Standards the FDA Applied

The FDA's bioequivalence standard for tadalafil requires that the 90% confidence interval for the ratio of generic to reference area under the curve (AUC) and maximum concentration (C-max) fall within 80.00% to 125.00%. Tadalafil's long plasma half-life of approximately 17.5 hours, noted in the current prescribing information, simplifies single-dose crossover study design because washout periods can be defined with high precision 5.

September 2018: When Generics Actually Launched

Eli Lilly's patent and exclusivity protections on Cialis expired on September 27, 2018. The FDA had already accepted and approved multiple ANDAs before that date, so several manufacturers launched the same day exclusivity dropped. Companies including Mylan, Teva, and Aurobindo were among the first ANDA holders cleared to distribute. Within 12 months of generic entry, the average retail price of a 20 mg tablet fell by more than 80% compared to the branded product, consistent with the FDA's own published analyses of generic competition effects on drug pricing 6.

What the Current Tadalafil Label Actually Says

The prescribing information for generic tadalafil mirrors the Cialis reference label in all clinically material respects because the ANDA pathway requires labeling parity. The current label, last revised in coordination with FDA-required updates to the PDE5 inhibitor class, covers four major content domains that prescribers and patients need to understand.

Dosing by Indication

For erectile dysfunction, on-demand dosing starts at 10 mg taken at least 30 minutes before sexual activity. The dose may be increased to 20 mg or decreased to 5 mg based on tolerability. Daily dosing for ED or BPH uses 2.5 mg once daily, with possible titration to 5 mg. The label specifies that once-daily tadalafil should be taken at approximately the same time each day without regard to sexual activity. For PAH, the approved dose is 40 mg (two 20 mg tablets) once daily 5.

Renal and Hepatic Dose Adjustments

Men with creatinine clearance 30 to 50 mL/min should begin at 5 mg on-demand, with a maximum of 10 mg no more frequently than every 48 hours. For creatinine clearance <30 mL/min or patients on hemodialysis, the maximum recommended dose is 5 mg. Patients with mild to moderate hepatic impairment (Child-Pugh Class A or B) should not exceed 10 mg on demand; tadalafil is not recommended in severe hepatic impairment. These renal and hepatic restrictions are printed verbatim in Section 2.6 and 2.7 of the current prescribing information, which manufacturers must reproduce without modification 5.

Drug Interactions the Label Flags

The label's Section 7 identifies three interaction categories that carry clinical weight.

Nitrates are an absolute contraindication. The combination of tadalafil with any organic nitrate, including nitroglycerin, isosorbide mononitrate, and amyl nitrite (poppers), can produce life-threatening hypotension. This contraindication carries a boxed-level warning in the drug interaction section. The FDA Adverse Event Reporting System (FAERS) contains documented cases of syncope and cardiac events tied to this combination 7.

Alpha-blockers require caution. Tamsulosin 0.4 mg once daily was studied with tadalafil in clinical pharmacology trials; the combination showed additive blood pressure lowering but was generally tolerable at the doses studied. Other alpha-blockers (doxazosin, terazosin) showed more pronounced drops, so the label recommends initiating tadalafil at the lowest dose when co-administering.

CYP3A4 inhibitors raise tadalafil exposure. Ketoconazole 400 mg daily increased tadalafil AUC by 312% in pharmacokinetic studies cited in the label. Ritonavir at steady state increased it by 124%. The label caps on-demand dosing at 10 mg every 72 hours when a potent CYP3A4 inhibitor is co-prescribed 5.

Tadalafil Safety Data: Post-Market Surveillance and Class-Wide Signals

FAERS Data and Reported Adverse Events

Since 2003, the FDA's FAERS database has accumulated tens of thousands of reports referencing tadalafil. The most common adverse events in spontaneous reporting are headache, flushing, dyspepsia, back pain, and myalgia, which closely track the adverse event rates seen in the pre-approval clinical trials 7. FAERS is a passive surveillance system, so reports represent a fraction of actual events and cannot be used to establish incidence rates directly. The FDA uses FAERS alongside the Sentinel System to look for disproportionate reporting signals that warrant label changes.

FDA Sentinel System Monitoring

The FDA Sentinel System, a distributed database covering more than 100 million patient records from U.S. Healthcare systems, monitors approved drugs including PDE5 inhibitors for emergent safety signals in real-world populations 8. Sentinel analyses can evaluate outcomes like non-arteritic anterior ischemic optic neuropathy (NAION), sudden hearing loss, and cardiovascular events in tadalafil users compared to matched controls. The FDA added NAION and sudden hearing loss warnings to the PDE5 inhibitor class label in 2007 based on post-market case reports and FAERS signal analysis, well before Sentinel was fully operational 9.

Cardiovascular Safety in Men With ED and Comorbidities

A retrospective cohort analysis published in JAMA Internal Medicine (Kloner et al.) found no excess cardiovascular event rate attributable to PDE5 inhibitors in men with stable coronary artery disease managed per American Heart Association guidelines, a finding consistent with the Princeton Consensus Panel III recommendations that classify these patients as generally low-risk for sexual activity 10. The AHA guidelines state that "sexual activity is reasonable for patients with cardiovascular disease who are stable and low risk," which aligns with permitting tadalafil use in appropriately screened men 11.

Vision and Hearing Warnings Added Post-Approval

The FDA issued a Drug Safety Communication in 2007 requiring all PDE5 inhibitor manufacturers to add a warning about sudden decrease in vision or hearing. NAION, a form of optic nerve ischemia, was reported at a rate that, while low, showed a temporal association with PDE5 inhibitor use in patients with pre-existing risk factors such as small optic disc cup-to-disc ratio, hypertension, diabetes, and hypercholesterolemia 9. The sudden hearing loss warning followed reports to FAERS describing unilateral hearing loss, tinnitus, or dizziness within hours of dosing.

Regulatory Milestones: A Timeline of Key Dates

2003 to 2011: Brand Era

• November 21, 2003: FDA approves Cialis (NDA 021368) for ED at 10 mg and 20 mg on-demand.
• 2007: Supplemental approval adds 2.5 mg and 5 mg daily-dose options for ED.
• 2008: NDA 022332 approved for Adcirca (tadalafil 20 mg) for PAH.
• 2011: Supplemental approval adds BPH indication; 5 mg once daily becomes the standard BPH dose.

2018 to Present: Generic Era

• September 27, 2018: Exclusivity expires; multiple ANDA holders launch simultaneously.
• 2019: Retail price competition drives average 20 mg tablet cost below $5 at major pharmacy chains, per GoodRx market data consistent with FDA generic competition analyses 6.
• 2021 to 2024: FDA continues ANDA approvals for additional manufacturers, expanding supply competition.
• 2023: FDA updates class-wide prescribing information format under the Physician Labeling Rule; generic label holders must conform within 30 days of any FDA-directed change.

The HealthRX clinical team has compiled a three-tier prescribing decision framework for tadalafil that maps indication, dosing schedule, and renal adjustment into a single reference tool for telehealth clinicians. The framework uses creatinine clearance thresholds of 50, 30, and <30 mL/min as branch points, cross-referenced against co-prescribed nitrates and CYP3A4 inhibitors, and outputs a recommended starting dose and maximum dose in real time during the prescribing workflow.

How Telehealth Prescribers Should Read the Generic Label

Generic tadalafil prescribing information is legally required to be substantively identical to the Cialis RLD label in all sections that affect patient safety. Section 1 (Indications and Usage), Section 2 (Dosage and Administration), Section 4 (Contraindications), Section 5 (Warnings and Precautions), and Section 7 (Drug Interactions) must reproduce the FDA-approved language without modification. Manufacturers may differ only in excipients listed in Section 11 (Description) and in certain inactive ingredient disclosures.

What "AB-Rated" Means for Prescribers

The FDA's Orange Book assigns an AB therapeutic equivalence rating to generic tadalafil products that have demonstrated bioequivalence and meet all manufacturing quality standards. An AB rating means pharmacists can substitute the generic for the brand, and vice versa, without prescriber authorization in most U.S. States. Prescribers writing "brand medically necessary" on a tadalafil prescription block that substitution, though payers rarely cover the branded product when generics are AB-rated 12.

Compounded Tadalafil Is Not FDA-Approved

Compounding pharmacies producing tadalafil formulations, including troches, sublingual drops, or topical creams, operate outside the ANDA approval framework. The FDA has not evaluated the bioequivalence, stability, or safety of compounded tadalafil in these forms. The FDA's guidance on compounding from bulk drug substances specifies that tadalafil is not on the 503A or 503B bulks list that would exempt it from standard new drug requirements 13. Prescribers should document medical necessity explicitly and counsel patients about the unverified bioavailability of non-ANDA tadalafil products.

Safety Monitoring Obligations for Prescribers

The absence of a Risk Evaluation and Mitigation Strategy (REMS) for tadalafil does not mean the drug requires no ongoing monitoring. Prescribers should assess cardiovascular risk at baseline using the Princeton Consensus Panel III stratification (low, intermediate, high risk for sexual activity), recheck blood pressure in men starting antihypertensive therapy concurrently, and ask about nitrate use at every refill visit because patients may begin short-acting nitrates between appointments.

Laboratory Monitoring Recommendations

No routine laboratory monitoring is mandated by the tadalafil label. A baseline serum creatinine or estimated glomerular filtration rate is clinically reasonable before initiating therapy in men over 60 or those with diabetes or hypertension, given the renal dose-adjustment requirements described above. The American Urological Association's 2018 erectile dysfunction guideline (updated 2024) does not mandate lab work before PDE5 inhibitor prescribing in otherwise healthy men but does recommend evaluation for underlying cardiovascular disease in men with new-onset ED 14.

Reporting Adverse Events

Prescribers and patients can report adverse events through the FDA MedWatch program online at fda.gov/medwatch or by calling 1-800-FDA-1088. For telehealth platforms, documenting and submitting MedWatch reports when a serious adverse event occurs is a regulatory best practice aligned with 21 CFR Part 314.81 post-marketing reporting obligations. The FDA uses these reports to update labeling and, when signals are strong enough, to issue Drug Safety Communications that require generic ANDA holders to update their labels within a defined timeframe 7.